Strategic report Corporate governance Financial statements Financial statements Notes to the consolidated financial statements continued 24.
Other current liabilities As at 31 December As at 31 December 2016 2015 2016 2015 $m $m $m $m Bank overdrafts 10 8 Deferred revenue 13 16 Import and export financing 63 58 Return and free goods provision 109 49 Short-term loans 4 Co-development and earnout payment note 32 4 3 Current portion of long-term loans note 28 44 45 Contingent consideration and liability note 43 123 117 115 Finance lease obligatations 1 1 Others 69 29 2016 2015 319 98 % % The weighted average interest rates paid were as follows: Co-development and earnout payment agreement: The liability mainly relates to the present value of future payments on a coBank overdrafts 4.32 6.19 development and earnout agreement.
As part of this agreement, milestone payments dependent on successful clinical development of Bank loans including the non-current bank loans 3.26 2.77 defined products are received by the Group.
In return of receiving such milestone payments, the Group has agreed to pay the contracting Eurobond 4.25 4.25 party a certain percentage of future sales of those products.
As at 31 December 2016 and 31 December 2015, the liability associated with Import and export financing 3.75 3.09 these earnout payments was adjusted to reflect the present value of the expected future cash outflows and the difference is presented as a finance cost income.
The current portion of the year-end balance is $4 million.
Import and export financing represents short-term financing for the ordinary trading activities of the business, and is mainly denominated Contingent consideration and liability represent the current portion of the Groups contractual contingent consideration and liabilities in US Dollars, Algerian Dinar, and in Saudi Riyals.
in relation to West-Ward Columbus acquisition of a total of $220 million note 30 and 43 and $119 million note 43 respectively.
During the year, the Group paid a total of $20 million in respect to the contingent consideration and $10 million for the contingent liability.
Trade and other payables The current portion of the year-end balance is $93 million related to the contingent consideration and another $30 million related to the As at 31 December 2016 2015 opening balance sheet contingent liability.
$m $m Others include indirect rebate liabilities across the Group.
Trade payables 172 139 Accrued expenses 157 122 Other payables 14 15 28.
Long-term financial debts As at 31 December 343 276 2016 2015 $m $m Other payables mainly include employees provident fund liability of $5 million 31 December 2015: $5 million, which mainly Long-term loans 270 141 represents the outstanding contributions to the Hikma Pharmaceuticals Ltd Jordan retirement benefit plan, on which the fund receives Long-term borrowings Eurobond 495 494 3.5% interest.
Less: current portion of long term loans note 24 44 45 Long-term financial loans 721 590 26.
Other provisions Breakdown by maturity: Other provisions represent the end of service indemnity provisions for employees of certain Hikma Group subsidiaries.
This provision is Within one year 44 45 calculated based on relevant laws in the countries where each Group company operates, in addition to their own policies.
In the second year 29 35 Movements on the provision for end of service indemnity: In the third year 171 20 2016 2015 In the fourth year 519 17 $m $m In the fifth year 2 513 1 January 28 25 Thereafter 5 Additions 1 5 765 635 Utilisation 2 2 Breakdown by currency: At 31 December 27 28 US dollar 746 589 Euro 1 3 Algerian dinar 2 6 Saudi riyal 1 1 Egyptian pound 13 33 Tunisian dinar 2 3 765 635 The loans are held at amortised cost.
Long-term loans amounting to $3 million 2015: $8 million are secured on certain property, plant and equipment.
Annual Report 2016 181 172 Hikma Pharmaceuticals plc Annual Report 2016 173
